ALFA Filings
Every announcement, straight from the exchange
Announcement type
Time
17 announcements with these filters
Ambey Laboratories Limited reported revenue from operations of ₹40.5 Cr and net profit of ₹2 Cr for Q4 FY26.
Ambey Laboratories Limited approved its audited FY26 financial results, reporting consolidated revenue of ₹141.54 Crore. The board also reviewed fund utilization and related party disclosures.
Dhansa Labs Limited submitted its annual SDD Compliance Certificate for the financial year 2026. This confirms regulatory adherence to SEBI insider trading monitoring requirements.
Ambey Laboratories Limited will change its name to Dhansa Labs Limited and its NSE symbol to DHANSA. The change is effective from June 01, 2026.
Dhansa Labs Limited allotted 3,63,043 equity shares following warrant conversions, raising ₹1.67 Crore. This exercise increases the company's paid-up capital and strengthens its equity base.
Ambey Laboratories scheduled a board meeting on May 29, 2026, to approve audited annual financial results. The company's trading window remains closed until May 31, 2026.
Dhansa Labs Limited submitted a missing Chartered Accountant's Certificate regarding its postal ballot process. The certificate confirms compliance with rebranding regulations for its name change.
Ambey Laboratories approved converting a ₹9.10 Crore inter-company loan into equity shares of its subsidiary. The restructuring strengthens the subsidiary's capital base without fresh cash outflow.
Dhansa Labs Limited allotted 3,60,870 equity shares following warrant conversions, totaling ₹1.66 Crore. This exercise increases the company's paid-up capital to ₹26.54 Crore.
Dhansa Labs Limited confirmed its non-applicability under the SEBI Large Corporate framework. This regulatory filing clarifies the company is exempt from specific debt-raising requirements.
Ambey Laboratories' subsidiary acquired land in Rajasthan for ₹0.93 Crore for a Biogas Pellet Project. This strategic acquisition supports the company's expansion into renewable energy.
Ambey Laboratories Limited allotted 3,63,043 equity shares following the conversion of warrants issued in August 2025. The company received the balance 75% payment aggregating to ₹1.25 Crore. Consequently, the paid-up share capital increased to 2,61,79,427 equity shares.
Dhansa Labs Limited (formerly Ambey Laboratories) allotted 3,63,043 equity shares following the conversion of warrants by Reema Pratit Patel. The company received ₹1.67 Crore representing the total issue price at ₹46 per share. Consequently, the company's paid-up equity share capital increased to ₹26.18 Crore.
Dhansa Labs Limited (formerly Ambey Laboratories) clarified to the NSE that recent share price movements are purely market-driven. The company confirmed it has no undisclosed price-sensitive information or impending announcements that could affect stock performance. It remains in compliance with all SEBI disclosure regulations.
Ambey Laboratories Limited has allotted 8,69,565 equity shares following the conversion of warrants. The company received a balance payment of ₹3.00 Crore (75% of the issue price) from two investors. The shares were issued at a price of ₹46 per share, including a ₹36 premium.
Ambey Laboratories Limited (now Dhansa Labs Limited) allotted 8,69,565 equity shares upon the conversion of warrants. The company received Rs. 3.00 Crore as the final 75% payment for these shares. Following this allotment, the company's paid-up equity capital increased to Rs. 25.82 Crore, with 1,00,00,000 warrants remaining outstanding.
Dhansa Labs Limited (formerly Ambey Laboratories Limited) promoters submitted their annual declaration confirming no encumbrance on their 1,74,99,420 equity shares for FY2026. This mandatory compliance filing under SEBI (SAST) Regulations confirms that promoter holdings remain unpledged and free of any direct or indirect liens.